Caring for Patients With Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk

The goal of this activity is to improve the knowledge and competence of learners to optimize treatment for patients with COVID.

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Target Audience

This activity is intended for oncology and infectious diseases specialists, including physicians and clinical pharmacists, advanced practice providers, nurses, and other healthcare professionals who care for cancer patients at risk for severe COVID-19 outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan COVID-19 prevention strategies for patients with cancer considering available guidelines along with new and emerging scientific data on next-generation mAbs
  • Identify patients with cancer who can benefit from COVID-19 prophylaxis with next-generation mAbs
  • Advance equitable access to pre- and/or postexposure COVID-19 prophylaxis strategies for patients with cancer through multispecialty and interprofessional collaboration

You may also be interested in

Appropriate Vaccinations for Patients in Survivorship
Clinician education on current vaccine recommendations can help providers encourage optimal immunizations to avoid the morbidity and mortality associated with vaccine-preventable infections.
Prophylactic Vaccines/Immunizations for Cancer Patients

Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Additional information
Supporters: 

Supported by an educational grant from AstraZeneca.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
07/23/2024
Course expires: 
07/23/2025
Cost:
$0.00

Cynthia Nguyen, PharmD, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
University of Chicago Medicine
Chicago, Illinois

Mazyar Shadman, MD, MPH
Innovators Network Endowed Chair
Associate Professor of Hematology and Oncology
Lymphoid Malignancies and Immunotherapy 
Fred Hutch Cancer Center and University of Washington
Seattle, Washington

Shmuel Shoham, MD
Professor of Clinical Medicine
Transplant and Oncology Infectious Diseases Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Cynthia Nguyen, PharmD, BCIDP

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Mazyar Shadman, MD, MPH
AbbVie, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker; Grant/Research Support
BeiGene: Consultant/Advisor/Speaker; Grant/Research Support
Bristol Myers Squibb: Consultant/Advisor/Speaker
Eli Lilly and Company: Consultant/Advisor/Speaker
Fate Therapeutics: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
Genmab A/S: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
Koi Biotherapeutics: Equity Interest/Stock Options
Merck & Co., Inc.: Consultant/Advisor/Speaker
MorphoSys/Incyte: Consultant/Advisor/Speaker
MorphoSys AG: Grant/Research Support
MustangBio: Consultant/Advisor/Speaker; Grant/Research Support
Nurix Therapeutics, Inc.: Consultant/Advisor/Speaker
Vincerx Pharma: Grant/Research Support

Shmuel Shoham, MD
Adagio Therapeutics: Consultant/Advisor/Speaker
Adamis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Ansun BioPharma: Grant/Research Support
Avir Pharma: Consultant/Advisor/Speaker
Cidara Therapeutics, Inc.: Grant/Research Support
F2G Ltd.: Grant/Research Support
Immunome: Consultant/Advisor/Speaker; Equity Interest/Stock Options
Karius: Consultant/Advisor/Speaker
Pfizer Inc.: Consultant/Advisor/Speaker
SCYNEXIS, Inc.: Consultant/Advisor/Speaker
Zeteo Biomedical LLC: Grant/Research Support

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-24-093-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until July 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing